Western Standard LLC - MERRIMACK PHARMACEUTICALS IN ownership

MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 55 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.

Quarter-by-quarter ownership
Western Standard LLC ownership history of MERRIMACK PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$23,353,180
+13.5%
1,894,013
+13.2%
21.09%
+19.0%
Q2 2023$20,571,295
+0.1%
1,672,4630.0%17.72%
-15.0%
Q1 2023$20,554,570
+17.3%
1,672,463
+9.3%
20.85%
+35.2%
Q4 2022$17,528,001
+298.6%
1,529,494
+30.5%
15.43%
+206.8%
Q3 2022$4,397,000
-41.8%
1,172,463
-7.6%
5.03%
-12.2%
Q2 2022$7,554,000
+11.1%
1,269,558
+8.3%
5.72%
-11.3%
Q1 2022$6,800,000
+48.3%
1,172,4630.0%6.46%
+138.1%
Q4 2021$4,584,000
-25.2%
1,172,463
-7.6%
2.71%
-22.2%
Q3 2021$6,132,000
-24.4%
1,269,5580.0%3.49%
-26.9%
Q2 2021$8,112,000
+27.7%
1,269,558
+25.5%
4.77%
+5.4%
Q1 2021$6,353,000
-8.9%
1,011,5710.0%4.53%
-43.2%
Q4 2020$6,970,000
+63.9%
1,011,571
-4.9%
7.97%
+65.1%
Q3 2020$4,253,000
+46.9%
1,063,267
+22.3%
4.83%
+39.1%
Q2 2020$2,895,000
+59.8%
869,354
+3.1%
3.47%
+107.6%
Q1 2020$1,812,000
-31.8%
842,9130.0%1.67%
-19.1%
Q4 2019$2,655,000
-65.0%
842,913
-50.0%
2.07%
-31.2%
Q3 2019$7,586,000
+100.7%
1,685,826
+169.8%
3.00%
+7.6%
Q2 2019$3,780,000
+27.9%
624,756
+46.9%
2.79%
+6.6%
Q1 2019$2,956,000
+409.7%
425,359
+182.9%
2.62%
+385.4%
Q4 2018$580,000150,3630.54%
Other shareholders
MERRIMACK PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Western Standard LLC 869,354$2,895,0003.47%
22NW, LP 1,241,896$4,136,0002.24%
Newtyn Management, LLC 1,199,606$3,995,0001.46%
WITTENBERG INVESTMENT MANAGEMENT, INC. 186,198$620,0000.35%
Yakira Capital Management, Inc. 66,934$223,0000.10%
Sepio Capital, LP 210,534$701,0000.08%
Nantahala Capital Management 747,635$2,490,0000.08%
Watson Rebecca 3,068$10,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 61,700$205,0000.00%
WEBSTER BANK, N. A. 3,055$10,0000.00%
View complete list of MERRIMACK PHARMACEUTICALS IN shareholders